Background/Objectives:Patients with acute myeloid leukemia (AML) have a higher propensity for adverse cardiovascular outcomes, primarily due to the toxic effects of chemotherapeutic agents. The purpose of this systematic review is to explore the association of acute myeloid leukemia treatment with adverse cardiovascular events.Methods:We systematically screened the literature for studies providing comparative data on cardiovascular toxicities in patients treated for acute myeloid leukemia. After the initial search, 3649 papers were screened and a final total number of 46 were included for the review process.Results:Common chemotherapeutic agents used in AML may cause cardiovascular (CV) toxicities. A plethora of pathophysiological mechanisms are incriminated for these effects. Drug combinations may increase the risk in a synergistic way. In addition, common mutations of AML, personal history of previous cardiovascular disease and impaired heart function carry an increased complication risk. Biomarkers, as well as multimodality imaging, may be used for the early detection of cardiovascular toxicities.Conclusions:Increased risks of CV toxicity and comorbidities are observed among AML patients. With all the available diagnostic modalities, early detection and CV prevention strategies can improve the patient’s prognosis and quality of life.
背景/目的：急性髓系白血病（AML）患者因化疗药物的毒性作用，其不良心血管事件的发生风险显著增高。本系统性综述旨在探讨急性髓系白血病治疗与不良心血管事件之间的关联。 方法：我们系统检索了提供急性髓系白血病治疗患者心血管毒性比较数据的研究文献。初步检索共筛选3649篇文献，最终纳入46篇进行综述分析。 结果：急性髓系白血病常用化疗药物可能引发心血管毒性，其病理生理机制复杂多样。联合用药可能以协同方式增加风险。此外，AML常见基因突变、既往心血管疾病史及心功能不全均会提升并发症风险。生物标志物与多模态影像学技术可用于早期检测心血管毒性。 结论：急性髓系白血病患者存在显著的心血管毒性及合并症风险升高。借助现有诊断手段，早期检测与心血管预防策略可改善患者预后及生活质量。
肿瘤(癌症)患者之家